Under BAK LOF that abolishes navitoclax SC kill, FOXO4-DRI retains residual SC kill
STATUS_LABEL: NEGATIVE
polarity: negative swarm_id: P14 card_sha256: 5f4d4cd1d33ee49a4dfca64c3d9dc87aa12c19cecd8c7efbbacbb22ad156e400 risk_class: research-discussion note: PASS_NEGATIVE — shipped as discussion (not claim/hypothesis). Soft-complete BAK LOF∩FOXO4-DRI residual vs navitoclax-abolished empty/non-match; matched H2H remains UNKNOWN.
Claim
On a matched senescent culture where BAK (Bcl-2 homologous antagonist/killer; Bak1) loss-of-function (or BAK block) abolishes navitoclax senescent-cell kill (pre-registered navitoclax residual kill under BAK LOF ≤20% of control-genotype navitoclax kill, or outside a pre-registered abolish band), FOXO4-DRI retains measurable residual SC kill — FOXO4-DRI kill under the same BAK LOF ≥20% of its control-genotype FOXO4-DRI kill (or outside a pre-registered null-residual band).
Why it matters
Complement of P13’s “≥ equal abolish”: if FOXO4–p53 entry still executes under BAK-alone LOF that fully gates navitoclax (Bax compensation / alternate route), pathway identity is not full BAK-execution identity. Soft-claims: discussion — FOXO4-DRI∩BAK residual/partial/independent soft-complete 0; sole related FOXO4-DRI apoptosis hit 41625068 cascade; matched BAK-alone residual H2H remains UNKNOWN; P13 ≥abolish ≠ residual; P8 Bax/Bak residual ≠ BAK-alone; P7/P8 Bax ≠ BAK. P5–P13 are not proof of this BAK-alone residual gate.
Mechanism sketch
FOXO4-DRI enters via FOXO4–p53; navitoclax via Bcl-2/Bcl-xL/Bcl-w; both may still require BAK as a multi-domain effector pore into MOMP — or FOXO4-DRI may keep partial BAK-independent / Bax-compensated death routes once navitoclax is fully BAK-gated. Endothelial FOXO4-DRI work frames a p53 / BCL-2 / Caspase-3 cascade without a BAK LOF residual-kill panel under navitoclax-abolish gating. Wei classical BAX/BAK gateway prior — doubly deficient cells resist tBID / multiple mitochondrial stimuli — is not a FOXO4-DRI residual panel under BAK-alone LOF. Assumption-kill of full BAK-execution identity: residual FOXO4-DRI under BAK LOF that abolishes navitoclax means distinct entry is not full BAK-execution identity; distinct from P13 abolish and from P8 Bax/Bak co-frame residual.
Prior art
- PMID 28340339 / DOI 10.1016/j.cell.2017.02.031 / PMC5556182 — FOXO4-DRI perturbs FOXO4–p53 → senescent-cell apoptosis (Baar 2017); not Bcl-xL occupancy; no BAK LOF residual arm.
- PMID 41625068 / DOI 10.3389/fbioe.2025.1729166 / PMC12852416 — endothelial FOXO4-DRI framed via p53 / BCL-2 / Caspase-3 (2025); cascade ≠ BAK residual H2H under navitoclax-abolish LOF.
- PMID 26711051 / DOI 10.1111/acel.12445 / PMC4854923 — navitoclax senolytic via Bcl-2 / Bcl-xL / Bcl-w; cell-type restricted (Zhu 2016).
- PMID 11326099 / DOI 10.1126/science.1059108 / PMC3049805 — BAX and BAK are a requisite gateway to mitochondrial dysfunction and death (Wei 2001) — classical MOMP prior, not FOXO4-DRI residual under BAK-alone LOF.
Baseline claimed
Under BAK LOF or block that abolishes navitoclax SC kill, FOXO4-DRI retains measurable residual SC kill on the same culture (or P13 ≥ equal abolish / P8 Bax/Bak residual / P5–P13 framing already settles BAK-alone residual independence).
Baseline measured
FOXO4–p53 entry LITERATURE (PMID 28340339). Downstream BCL-2/caspase-3 framing LITERATURE without BAK residual H2H (PMID 41625068). Navitoclax Bcl-2-family senolytic LITERATURE (PMID 26711051). Wei BAX/BAK gateway LITERATURE as classical MOMP prior (PMID 11326099). Matched BAK LOF (abolishing navitoclax) × residual FOXO4-DRI SC kill UNKNOWN (soft-complete FOXO4-DRI∩BAK∩(residual|partial|independent|retain*) = 0; sole related FOXO4-DRI apoptosis hit = 41625068 cascade, non-match). Residual ≥20% of control-genotype FOXO4-DRI kill under BAK LOF that abolishes navitoclax PREDICTION. P5–P13 do not already prove this residual — P13 ≥abolish ≠ residual; P8 Bax/Bak residual ≠ BAK-alone; P7/P8 Bax ≠ BAK.
Actionable limitations
- Do not treat P5–P13 as proving P14 — P13 abolish and P8 Bax/Bak residual did not run BAK-alone residual under LOF that abolishes navitoclax; empty soft-complete ≠ demonstrated residual kill; P13 ≥abolish ≠ residual; P7/P8 Bax ≠ BAK.
- Gating condition is strong — assay requires BAK LOF that abolishes the navitoclax arm first; partial navitoclax resistance misreads as FOXO4-DRI residual.
- Caspase-3 cascade ≠ BAK residual — 41625068 implicates p53/BCL-2/Caspase-3 without genetic BAK residual measurement; Wei ≠ FOXO4-DRI residual panel; Bax compensation under BAK-alone remains PREDICTION until scored.
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| FOXO4_DRI_p53_entry | LITERATURE | FOXO4 peptide disrupts FOXO4–p53 in senescent cells → apoptosis (Baar 2017) | FOXO4–p53 axis entry, not Bcl-xL occupancy (PMID 28340339) |
| FOXO4_DRI_p53_BCL2_Caspase3_framing | LITERATURE | Senescent endothelium FOXO4-DRI via p53/BCL-2/Caspase-3 (2025) | mitochondrial/effector framing downstream of FOXO4–p53 (PMID 41625068) — not BAK residual H2H under navitoclax-abolish LOF |
| navitoclax_Bcl2_family_senolytic | LITERATURE | ABT-263 senolysis in restricted SC panels (Zhu 2016) | Bcl-2/Bcl-xL/Bcl-w dependent; cell-type restricted (PMID 26711051) |
| Wei_BAX_BAK_MOMP_gateway_prior | LITERATURE | Cells lacking both Bax and Bak resist tBID-induced cytochrome c release and multiple mitochondrial apoptotic stimuli (Wei 2001) | classical BAX/BAK multi-domain effector gateway prior (PMID 11326099) — not FOXO4-DRI residual under BAK-alone LOF; no KD invented |
| matched_BAK_LOF_residual_FOXO4_panel | UNKNOWN | Same senescent culture — BAK LOF or BAK block vs control × FOXO4-DRI vs navitoclax; require navitoclax abolish under BAK LOF, then score FOXO4-DRI residual viability (+ MOMP/caspase readout); optional Bax arm contrast | dedicated BAK-alone residual panel not found (soft-complete FOXO4-DRI∩BAK∩(residual |
| FOXO4_residual_under_BAK_LOF_that_abolishes_navitoclax | PREDICTION | Pre-registered matched culture; BAK LOF must abolish navitoclax first, then score FOXO4-DRI residual kill vs its control-genotype arm | navitoclax kill under BAK LOF ≤20% of control-genotype navitoclax kill (or outside pre-registered abolish band) AND FOXO4-DRI kill under same BAK LOF ≥20% of control-genotype FOXO4-DRI kill (or outside pre-registered null-residual band); α/N pre-specified — do not invent observed % or dosing |
| competing_partial_navitoclax_gate_misread | PREDICTION | Same design; falsifier / inconclusive path if apparent FOXO4-DRI residual coincides with incomplete navitoclax abolish under BAK LOF | incomplete navitoclax gate allowed as pre-registered competing outcome / QC fail (inconclusive_if ≠ refute_if) — does not invent a residual result |
Ablate
- remove matched BAK LOF (or BAK block) panel that first abolishes navitoclax, then scores FOXO4-DRI residual on the same culture: Without the gated residual panel, separate LITERATURE legs cannot show FOXO4-DRI retains kill when navitoclax is fully BAK-gated.
- remove navitoclax-abolish gating condition (strong BAK LOF / abolish band): Without requiring navitoclax abolish first, partial resistance misreads as FOXO4-DRI residual and the claim loses its momp-execution-gate contrast.
- remove P5–P13≠proof + P13-abolish≠residual + P8-Bax/Bak-residual≠BAK-alone + soft-complete-empty≠residual + cascade≠BAK-residual + P7/P8-Bax≠BAK + Wei≠FOXO4-DRI-panel discipline: Treating P13 abolish, P8 Bax/Bak residual, empty PubMed, 41625068 cascade, or Wei classical gateway as already deciding BAK-alone residual would invent a LOF residual result left UNKNOWN.
Refute if
On the pre-registered matched panel where BAK LOF / BAK block abolishes navitoclax kill, FOXO4-DRI residual kill also falls inside the null-residual band (FOXO4-DRI kill under BAK LOF <20% of control-genotype, or inside band) — full BAK-execution identity / ≥ equal abolish survives and residual BAK-independence / Bax-compensation fails.
Ask a human
Lock one senescent system sensitive to both senolytics, BAK LOF vs BAK block tool, navitoclax-abolish QC, and viability + MOMP/caspase readout before claiming residual FOXO4-DRI under BAK LOF; do not treat P5–P13 as proof; P13 ≥abolish ≠ residual; P8 Bax/Bak residual ≠ BAK-alone; P7/P8 Bax ≠ BAK; no dosing.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=momp-execution-gate · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=P13 (≥abolish ≠ residual); P8 (Bax/Bak residual ≠ BAK-alone); P7 (Bax/Bak abolish ≠ BAK-alone residual); P5–P12 ≠ BAK-alone residual proof; P7/P8 Bax ≠ BAK